Eradication of helicobacter pylori: A clinical update

MedGenMed Medscape General Medicine

Volumn 6, Issue 1, 2004, Pages

  Romano, Marco ^a   Cuomo, Antonio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; BISMUTH SALT; CLARITHROMYCIN; LACTOFERRIN; LEVOFLOXACIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE DERIVATIVE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH JUICE; STOMACH PH; CLINICAL PRACTICE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 25144466064     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Megraud F, Brassens-Rabbe MP, Denis F. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-1873.
2. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16 (Suppl. 1):3-15.
3. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999;179:1523-1530.
4. Rauws EAJ, Tytgat GNY. Cure of duodenal ulcer disease associated with eradication of Helicobacter pylori. Lancet 1990;2:12233-1235.
5. Zarrilli R, Ricci V, Romano M. Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol 1999;1:93-99.
6. Ricci V, Zarrilli R, Romano M. Voyage of Helicobacter pylori in human stomach: Odyssey of a bacterium. Digest Liver Dis. 2002;34: 2-8.
7. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345: 784-789.
8. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev Cancer 2002; 2: 28-37.
9. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:647-654.
10. Iwahi T, Satoh H, Hakao M. Lansoprazole: a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991;35:490-496.
11. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358-367.
12. Gustarson LE, Kaiser JF, Edmonds AL. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995;39:2078-2083.
13. Calafatti AS, Santos A, Da Silva CMF, et al. Transfer of metronidazole to gastric juice: impact of Helicobacter pylori infection and omeprazole. Scand J Gastroenterol. 2000;35:699-704.
14. Pedrazzoli J Jr, Calafatti SA, Ortiz RA, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol. 2001;36:1248-1253.
15. Malfertheiner P, Megraud F, O'Morain C. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2000;16:167-180.
16. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori in patients with non-ulcer dyspepsia. N Engl J Med. 1998;339:1871-1875.
17. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med. 1998;339:1869-1874.
18. Malfertheiner P, Mossner J, Fishbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2003;18:615-626.
19. Feldman M, Cryer B, Mallat D, Go MF. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol. 2001; 96:1751-1757.
20. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975-979.
21. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients in with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-1447.
22. Gillen D, Wirz AA, Ardille JE, McColl KEL. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology. 1999;116: 239-247.
23. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon ATR. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121:1120-1126.
24. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux oesophagitis treated with omeprazole or fundoplication. N Engl J Med. 1991;325:1127-1131.
25. Gisbert JP, Pajares JM, Racz I. The year in Helicobacter pylori therapy 2001. Curr Opin Gastroenterol. 2001;17(Suppl 1):S47-S54.
26. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther. 2002;16:315-324.
27. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based "rescue therapy" for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther. 2000;14:311-316.
28. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:553-560.
29. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627-633.
30. Chi C-H, Lin C-Y, Sheu B-S, Yang H-B, Huang A-H, Wu J-J. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18: 347-353.
31. Gerrits MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbroucke-Grauls CM, Kusters JG. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2229-2233.
32. Kwon DH, Kim JJ, Lee M, et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:3203-3205.
33. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology. 1998;115:1272-1278.
34. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology. 1998; 115:1272-1277.
35. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycicn and amoxicillin or metronidazole. Aliment Pharmacol Ther. 1999;13:719-729.
36. Iovene MR, Romano M, Pilloni AO, et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy. 1999; 45:8-14.
37. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vanderbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother. 1999;43:415-511.
38. Deltenre MA. Economics of Helicobacter pylori eradication therapy. Eur J Gastroenterol Hepatol. 1997;9 (Suppl 1): S27-S29.
39. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost-saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol. 2003;1:273-278.
40. Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:1639-1643.
41. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost-effective? Am J Gastroenterol. 1999; 94: 725-729.
42. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 2003;17:719-726.
43. Canducci F, Cremonini F, Armuzzi A, et al. Probiotics and Helicobacter pylori eradication. Digest Liver Dis. 2000;34(suppl 2):S81-S83.
44. Di Mario F, Aragona G, Dal B N, et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis. 2003;35:706-711.
45. Guttner Y, Windsor HM, Viiala CH, Marshall BJ. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:125-130.